CHATSWORTH, Calif., Oct. 31, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables, and a developer of high-value personalized diagnostics tests, today announced that it will it will host a Technology Day for investors and analysts on Friday, December 2, 2011 from 8:00am to 10:30am Eastern time, at the New York Athletic Club located at 180 Central Park South in New York, New York.
César García, the Company's Chairman and Chief Executive Officer, will host the meeting. During the meeting Mr. García will provide updates on the Company's product pipeline and core business strategy. Dr. Tom Adams, Corporate Vice President, Chief Technology Officer of IRIS and Head of Iris Molecular Diagnostics will then provide an overview of NADiA ProsVue, which will be followed by a presentation given by Dr. Judd W. Moul, Professor and Director of the Duke Prostate Center at Duke University Medical Center. Dr. Moul will discuss his current practice patterns, as well as the clinical utility of NADiA ProsVue and potential market opportunity for the test. In addition, the Company's Chief Financial Officer, Amin Khalifa, will provide a financial update and preliminary 2012 guidance for the Company. Following the presentations, there will be a question and answer session.
A live audio webcast of the presentation of the IRIS International Investor Breakfast will be accessible through the Company's investor relations website at www.proiris.com. An archived edition of the presentation will be available later that day and will be available for at least 30 days afterwards.
About IRIS International, Inc.
IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 3,200 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and body fluids. In addition, the Company's personalized medicine group has a high complexity CLIA-certified laboratory as a direct commercial channel for the Company's NADiA® ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious disease. For more information, please visit www.proiris.com.